AM
Therapeutic Areas
Lexicon Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| INPEFA (sotagliflozin) | Heart Failure | Approved |
| LX9211 | Diabetic Peripheral Neuropathic Pain (DPNP) | Phase 2 |
Leadership Team at Lexicon Pharmaceuticals
LC
Lonnel Coats
Chief Executive Officer
JL
Jeffrey L. Wade
President, Chief Financial Officer & Corporate Secretary
CA
Craig A. Granowitz, M.D., Ph.D.
Senior Vice President & Chief Medical Officer
AJ
Alan J. Main, Ph.D.
Executive Vice President, Research & Development and Chief Scientific Officer
BT
Brian T. Crum
Senior Vice President, Corporate Affairs & Investor Relations
DL
David L. Southwell
Director
JF
John F. Kouten
Director
KA
Keith A. Sutton
Director
HP
H. Paul Dorman
Director
WJ
W. James O'Shea
Director